Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 6/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 6/20 | 0.40 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.40 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.40 |
| ▸ | POLRMT | O00411 | 1/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.37 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.37 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.37 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.35 |
| ▸ | ADK | P55263 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21078516 | 0.88 | P2RY1 (0.42) | PRMT5WDR77P2RY1P2RY2P2RY11 | |
| SCHEMBL31228569 | 0.88 | P2RY1 (0.42) | PRMT5WDR77P2RY1P2RY2P2RY11 | |
| SCHEMBL16374203 | 0.87 | P2RY1 (0.53) | P2RY1P2RY2P2RY11P2RX1P2RX3 | |
| SCHEMBL16368356 | 0.87 | P2RY1 (0.53) | P2RY1P2RY2P2RY11P2RX1P2RX3 | |
| SCHEMBL16368367 | 0.82 | PRMT5 (0.44) | PRMT5WDR77P2RY1P2RY2P2RY11 | |
| SCHEMBL16377074 | 0.82 | PRMT5 (0.44) | PRMT5WDR77P2RY1P2RY2P2RY11 | |
| SCHEMBL23171664 | 0.81 | P2RX3 (0.48) | PRMT5WDR77P2RY1P2RY2P2RX1 | |
| SCHEMBL16368346 | 0.81 | P2RX3 (0.48) | PRMT5WDR77P2RY1P2RY2P2RX1 | |
| SCHEMBL16374048 | 0.81 | P2RX3 (0.48) | PRMT5WDR77P2RY1P2RY2P2RX1 | |
| SCHEMBL16374235 | 0.81 | P2RX3 (0.48) | PRMT5WDR77P2RY1P2RY2P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2018-03-22 | — | — | US | disclosed |
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | PRMT5 1351/4885WDR77 1808/4885P2RY1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.